Risperidone Monotherapy for Psychotic Depression Unresponsive to Other Treatments
J Clin Psychiatry 1998;59(11):624 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Sir: Risperidone, an atypical antipsychotic agent, has been reported to yield acute antidepressant effects in certain patients with schizophrenia, schizoaffective disorder, or psychotic depression. Furthermore, it has been demonstrated that adding risperidone to preexisting antidepressants can improve chronic depression. However, it remains unclear whether risperidone alone is effective in treating psychotic depression resistant to other treatments; earlier reports concerning risperidone monotherapy for psychotic depression did not reveal subjects’ previous treatment responses.